Literature DB >> 6319159

Adenosine relaxes the aorta by interacting with an A2 receptor and an intracellular site.

M G Collis, C M Brown.   

Abstract

The purpose of this study was to determine whether the adenosine receptor that mediates relaxation of the noradrenaline-contracted guinea-pig aorta is of the A1 or A2 subtype. 5'-N-ethylcarboxamide adenosine (NECA) and 5'-N-cyclopropylcarboxamide adenosine (NCPCA) were about 100 times more potent as relaxants of the aorta than L-N6-phenylisopropyladenosine (L-PIA) and N6-cyclohexyladenosine. L-PIA was 3 times more potent than D-PIA. These relaxations were not altered by the purine transport inhibitor dipyridamole, but were attenuated by the cell surface adenosine receptor antagonist 8-phenyltheophylline. Adenosine and 2-chloroadenosine differed from NECA and NCPCA since they evoked greater maximal relaxations and their submaximal responses were less sensitive to blockade by 8-phenyltheophylline. These differences were abolished by dipyridamole which indicates that they were due to an intracellular action of adenosine and 2-chloroadenosine. The intracellular 'P-site' agonist, 9-beta-D-xylofuranosyladenine evoked small relaxations that were attenuated by dipyridamole but were unaffected by 8-phenyltheophylline. These results indicate that adenosine can relax the aorta via interactions with a cell surface A2 receptor and with an intracellular site.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6319159     DOI: 10.1016/0014-2999(83)90529-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  27 in total

1.  The effects of purine compounds on the isolated aorta of the frog Rana temporaria.

Authors:  G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

2.  Differential development of adenosine A1 and A2b receptors in the rat duodenum.

Authors:  J A Peachey; S M Hourani; I Kitchen
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Adenosine in heart and lung disease. Proceedings of the first Cardiothoracic Institute Workshop. 30 March 1988, London. Abstracts.

Authors: 
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

4.  Effects of P1 and P2Y purinoceptor antagonists on endothelium-dependent and -independent relaxations of rat mesenteric artery to GTP and guanosine.

Authors:  P Vuorinen; X Wu; P Arvola; H Vapaatalo; I Pörsti
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Adenosine receptors mediate both contractile and relaxant effects of adenosine in main pulmonary artery of guinea pigs.

Authors:  A J Szentmiklósi; A Ujfalusi; A Cseppentö; K Nosztray; P Kovács; J Z Szabó
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

6.  Interactions between A(2A) adenosine receptors, hydrogen peroxide, and KATP channels in coronary reactive hyperemia.

Authors:  Maryam Sharifi-Sanjani; Xueping Zhou; Shinichi Asano; Stephen Tilley; Catherine Ledent; Bunyen Teng; Gregory M Dick; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-22       Impact factor: 4.733

7.  A1- and A2-selective adenosine antagonists: in vivo characterization of cardiovascular effects.

Authors:  G Evoniuk; K A Jacobson; M T Shamim; J W Daly; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

8.  Purine metabolite inosine is an adrenergic neurotrophic substance for cultured chicken sympathetic neurons.

Authors:  A D Zurn; K Q Do
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

9.  Activation of multiple sites by adenosine analogues in the rat isolated aorta.

Authors:  D J Prentice; S M Hourani
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  Functional characterization of three adenosine receptor types.

Authors:  M F Gurden; J Coates; F Ellis; B Evans; M Foster; E Hornby; I Kennedy; D P Martin; P Strong; C J Vardey
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.